PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.1074
https://www.valueinhealthjournal.com/article/S1098-3015(21)01291-2/fulltext
Section Title :
Section Order :
10566
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01291-2&doi=10.1016/j.jval.2021.04.1074